Market capitalization | $257.23m |
Enterprise Value | $-6.25m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.10 |
EV/Sales (TTM) EV/Sales | -0.05 |
P/S ratio (TTM) P/S ratio | 1.86 |
P/B ratio (TTM) P/B ratio | 1.06 |
Revenue growth (TTM) Revenue growth | -13.98% |
Revenue (TTM) Revenue | $138.39m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
11 Analysts have issued a Arcturus Therapeutics Ltd forecast:
11 Analysts have issued a Arcturus Therapeutics Ltd forecast:
Dec '24 |
+/-
%
|
||
Revenue | 138 138 |
14%
14%
|
|
Gross Profit | 135 135 |
-
|
|
EBITDA | -36 -36 |
786%
786%
|
EBIT (Operating Income) EBIT | -39 -39 |
466%
466%
|
Net Profit | -81 -81 |
204%
204%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Head office | Israel |
CEO | Joseph Payne |
Employees | 176 |
Founded | 2013 |
Website | www.arcturusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.